GenFleet Pharmaceuticals

GenFleet Pharmaceuticals (2595.HK) is a globally positioned innovative drug development enterprise, focusing on highly unmet clinical needs in the fields of oncology and immune diseases. Centering on disease biology mechanisms and translational medicine, the company builds and leverages its advantages of an independent and integrated R&D system, primarily targeting innovative targets and indications that lack clinical validation, and holds global independent intellectual property rights. Since its establishment in 2017, GenFleet has built a pipeline including multiple self-developed 'First-in-Class' large and small molecule projects, with several products in global multicenter clinical trials in China, Europe, and the United States, including multiple late-stage or pivotal clinical studies.

Dabert® (Fulzerasib) is the first product approved for marketing in China among GenFleet's pipeline, and it is the first domestic and the third globally marketed KRAS G12C inhibitor. Currently, the company has formed an integrated and deepening matrix for RAS-targeted therapies, including selective and pan-RAS inhibitors across multiple targets and molecular types. Multiple products are at the leading edge in the same-target track both domestically and internationally, and research data have repeatedly been featured in breakthrough research abstracts and oral presentations at international academic conferences. Meanwhile, the company actively expands the development of other 'First-in-Class' targeted drugs, creating globally pioneering multi-type dual-target therapies through synergistic mechanisms; and, combined with innovations in clinical needs and treatment concepts, it uses its product matrix to enter large indication markets such as pancreatic cancer, non-small cell lung cancer, and cachexia.

GenFleet has been awarded the titles of National 'Little Giant' Specialized, Refined, Differentiated, and Innovative Enterprise and National High-Tech Enterprise, and has received recognition as a Shanghai Specialized, Refined, Differentiated, and Innovative SME, a Shanghai Multinational Corporation R&D Center, and a Shanghai Enterprise Technology Center. In recent years, the company has continuously deepened its commercial cooperation network, having entered into strategic licensing agreements with multiple domestic and overseas listed companies or conducted 'First-in-Class' clinical collaborations, all with positive progress.